Literature DB >> 35132002

Brief Communication PD1-related Nephrotoxicity: Optimizing Its Clinical Management Through Histopathologic Features.

Anna M Di Giacomo1,2, Andrea Guarnieri3, Sergio A Tripodi4, Marta Maccari5, Nicoletta Mancianti3, Garosi Guido3, Giulia Rossi1, Maria Grazia Daffinà5, Luana Calabrò1, Monica Valente1, Michele Maio1,2,5.   

Abstract

Immune-related nephrotoxicity (ir-N) is a rare adverse event of immune-checkpoint(s) inhibitors (ICI) therapy and its clinical management is still debated. Among 501 consecutive ICI-treated patients at our Institution, 6 who developed an ir-N with clinical signs suggestive for an acute kidney injury underwent kidney biopsy. Histology showed an acute tubule-interstitial nephritis, simulating the scenario of acute T-cell-mediated kidney transplant rejection. Thus, the management of allograft kidney rejection routinely utilized at our clinic was implemented, leading to rapid renal function improvement. Histologic features supporting the definition of an immune-mediated acute kidney injury in ICI-treated patients may help optimizing the clinical management of ir-N.
Copyright © 2022 Wolters Kluwer Health, Inc. All rights reserved.

Entities:  

Mesh:

Year:  2022        PMID: 35132002     DOI: 10.1097/CJI.0000000000000412

Source DB:  PubMed          Journal:  J Immunother        ISSN: 1524-9557            Impact factor:   4.456


  2 in total

Review 1.  The role of kidney biopsy in immune checkpoint inhibitor nephrotoxicity.

Authors:  Emily M Moss; Mark A Perazella
Journal:  Front Med (Lausanne)       Date:  2022-08-10

2.  Immune Checkpoint Inhibitors' Associated Renal Toxicity: A Series of 12 Cases.

Authors:  Kostas Palamaris; Dimitrios Alexandris; Kostas Stylianou; Ioannis Giatras; Anastasios Stofas; Christina Kaitatzoglou; Magda Migkou; Dimitrios Goutas; Erasmia Psimenou; Eleni Theodoropoulou; Stamatios Theocharis; Nektarios Alevizopoulos; Efstathios Kastritis; Alexandros Gerakis; Harikleia Gakiopoulou
Journal:  J Clin Med       Date:  2022-08-16       Impact factor: 4.964

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.